Antibody-targeted immunotherapy for treatment of malignancy

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 125-145

  White, C A ^a   Weaver, R L ^a   Grillo Lopez A J ^a  

^a BIOGEN   (United States)

Author keywords

Ibritumomab tiuxetan; IDEC Y2B8; Monoclonal antibody; Non Hodgkin's lymphoma; Radioimmunotherapy; Rituximab

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CHLORAMBUCIL; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EDRECOLOMAB; EPIRUBICIN; EPRATUZUMAB; ETOPOSIDE; FAMCICLOVIR; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IDIOTYPIC ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY M 195; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

CANCER IMMUNOTHERAPY; CARCINOMA; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 0035091343     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.125     Document Type: Review

References (111)

1. Continuous cultures of fused secreting antibody of redefined specificity
2. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins
3. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins
4. Comparative metabolism and retention of I-125, Y-90, and In-111 radioimmunoconjugates by cancer-cells
5. 90 Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
6. 111In-labeled T101 monoclonal antibody
7. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma
8. Therapy of lymphoma directed at idiotypes
9. 90y-conjugated antiidio-type monoclonal antibody
10. The future of I-131 anti-B1 antibody therapy - Is initial treatment an option?
11. A phase II study of anti-B4-blocked ricin (Anti-Br-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL)
12. Adjuvant immunotoxin therapy with anti-B-4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma
13. Cloning and expression of a chimeric anti-CD20 monoclonal antibody
14. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
15. "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4
16. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program
17. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
18. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
19. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
20. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion
21. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
22. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
23. Phase I immunotoxin trial in patients with B-cell lymphoma
24. Human macrophages armed with murine immunoglobulin G2a antibodies to tumours destroy human cancer cells
25. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Sevenyear outcome of a multicenter randomized trial
26. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
27. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
28. Humanization of an anti-p185HER2 antibody for human cancer therapy
29. Targeting the c-erb-2 proto-oncogene with monoclonal antibodies
30. Herceptin® (trastuzumab)
31. Monoclonal anti-idiotype therapy of B-cell lymphoma
32. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells
33. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
34. A clinical trial of anti-idiotype therapy for B cell malignancy
35. Shared idiotypes expressed by human B-cell lymphomas
36. Treatment of B-cell lymphomas with antiidiotype antibodies alone and in combination with alpha interferon
37. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
38. The CAMPATH antigen (CD52)
39. Phase II multicentre study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia
40. Multicentre study of CAMPATH- 1H in patients with chronic lymphocytic leukaemia (B-CLL) refractory to fludarabine
41. Immunosuppressive toxicity of CAMPATH 1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
42. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
43. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas
44. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
45. Chimeric anti-CD20 (DEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
46. Rituxan (rituximab IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma
47. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
48. IDEC-C2B8: Final report on a phase II trial in relapsed non-Hodgkin's lymphoma
49. Rituximab: Phase II (PII) retreatment (ReRx) study in patients (pts) with lowgrade or follicular (LG/F) NHL
50. Rituximab: First report of a Phase II (PII) trial in NHL patients (pts) with bulky disease
51. Rituximab/CHOP chemoimmunotherapy in patients (Pts) with low grade lymphoma (LG/F NHL): Progression free survival (PFS) after three years (median) follow up
52. Prognostic factors for non-Hodgkin's lymphoma (NHL) PTS treated with chemotherapy (CRX) may not predict response duration in patients (PTS) treated with immunotherapy: Rituximab experience
53. A Phase III pivotal trial of IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma
54. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
55. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
56. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
57. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study
58. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
59. Radiolabeled-antibody therapy of Bcell lymphoma with autologous bone marrow support
60. A unique antigen on mature B cells defined by a monoclonal antibody
61. High dose radiolabeled antibody therapy of lymphoma
62. Imaging and treatment of B-cell lymphoma
63. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies
64. 131I] anti-B1 (anti-CD20) antibody
65. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
66. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas
67. 90Yttrium anti-CD20 monoclonal
68. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent Bcell lymphoma
69. Monoclonal antibody-based therapies for hematologic malignancies
70. Treatment of B-cell lymphoma with I-131 labeled murine monoclonal antibodies
71. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
72. 131I-anti-B1 (anti-CD20) radioimmunotherapy (RIT) for refractory B-cell lymphoma
73. 131I anti-B1 radioimmunotherapy of non-Hodgkin's lymphoma without marrow transplantation: Expanded phase I study results
74. A phase II trial of iodine-131-labeled anti-CD20 (B1) antibody therapy with bone marrow transplantation for relapsed non-Hodgkin's lymphomas
75. Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice
76. Radiolabeled antibody: Iodine versus radiometal chelates
77. Biotechnology and nuclear medicine: Radiology brings biotechnology into the picture to combat cancer
78. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy
79. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy
80. 111In-labeled monoclonal antibody 96.5
81. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies
82. The effect of increasing "cold" antibody dose on prostatic cancer metastases detection and on body distribution of PAY-276 monoclonal antibody
83. 97 monoclonal antibody in patients with metastatic malignant melanoma
84. I-131 anti-b1 antibody for previously untreated follicular lymphoma (FL); clinical and molecular remissions
85. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131-LYM-1 antibody
86. 90YhLL2 anti-CD22 MAB in patients with Bcell malignancies
87. TM radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma
88. Multicenter Phase III study of iodine-131 tositumomab (anti-BI antibody) for chemotherapy-refractory lowgrade or transformed low-grade non-Hodgkin's lymphoma (NHL)
89. Radiolabeled antibody therapy of B-cell lymphomas
90. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stemcell rescue
91. Iodine-131 anti-B1 antibody for Bcell lymphoma: An update on the Michigan Phase I experience
92. A revolution in the treatment of non-Hodgkin's lymphoma
93. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2
94. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
95. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
96. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting
97. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids
98. Cell and environment interactions in tumor microregions: The multicell spheroid model
99. Scintigraphy with In-111labeled monoclonal antitumor antibodies: Kinetics, biodistribution and tumor detection
100. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
101. Engineered humanized dimeric forms of IgG are more effective antibodies
102. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia
103. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
104. 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium
105. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
106. Prospective randomized controlled study of Zevalin™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: Report of interim results
107. Zevalin™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): Interim results
108. Reduced-dose Zevalin™ radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: Report of interim results of a Phase II trial
109. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC Y2B8 Phase I/II 90 yttrium trial
110. Responders to rituximab show continued tumor regression over time and progression-free survival that correlates with response classification
111. Zevalin™ radioimmunotherapy (RIT) for B-cell non-Hodgkin's lymphoma (NHL): Biodistribution and dosimetry results